Market Overview:

The United States vaccines market size is projected to exhibit a growth rate (CAGR) of 5.91% during 2024-2032. The regulatory support and approval processes, the emerging infectious diseases, the rise of telehealth and remote healthcare services, the favorable healthcare policies, and the international collaborations and partnerships are some of the factors propelling the market.

Vaccines are biological substances designed to stimulate the immune system to recognize and fight specific pathogens, such as viruses or bacteria. They play a crucial role in preventing infectious diseases and promoting public health. Vaccines are typically composed of weakened or inactivated forms of the targeted microorganism or specific components, such as proteins or genetic material. When administered, vaccines prompt the immune system to produce an immune response, including the production of antibodies and the development of immune memory. This immune memory allows the body to recognize and rapidly respond to the actual pathogen if encountered in the future, providing protection against infection and often preventing the onset of diseases. Vaccination programs have been instrumental in controlling and eradicating infectious diseases globally. Common vaccines include those for measles, mumps, rubella, polio, influenza, hepatitis, and more. In addition to individual protection, vaccines contribute to herd immunity, reducing the overall spread of infectious agents within communities. Continuous research and advancements in vaccine technology, such as mRNA vaccines, have expanded the scope and efficacy of vaccination efforts. Vaccines have been pivotal in controlling pandemics, as evidenced by their role in combating diseases like smallpox and, more recently, in the global response to the COVID-19 pandemic. They represent a powerful tool in public health, preventing illness, reducing the burden on healthcare systems, and saving countless lives by effectively bolstering the body's immune defenses against a wide array of infectious agents.

United States Vaccines Market Trends:

The market in the United States is majorly driven by the advancements in vaccine development. In line with this, the COVID-19 pandemic has accelerated vaccine research, production, and distribution efforts. The urgency to address the global health crisis has led to increased investments, collaborations, and government support for vaccine development, contributing significantly to market growth. Furthermore, the rising awareness of the importance of vaccination in preventing infectious diseases has driven demand. Routine vaccinations for diseases like influenza, measles, mumps, rubella, and hepatitis have gained prominence as individuals and healthcare providers recognize the value of immunization in maintaining public health. Government initiatives and public health programs play a pivotal role in driving the vaccine market. Programs such as the Vaccines for Children (VFC) program, which provides vaccines to eligible children, and the Adult Immunization Initiative contribute to increased vaccine accessibility and utilization. Additionally, the emergence of innovative vaccine technologies has expanded the market. mRNA vaccine platforms, as demonstrated by the success of COVID-19 vaccines, showcase the potential for rapid development and effectiveness against a variety of pathogens. This has spurred interest and investment in novel vaccine approaches, driving market growth. The aging population in the United States is a significant factor influencing the vaccine market. As individuals age, there is a higher susceptibility to certain diseases, necessitating vaccinations to prevent complications. This demographic shift contributes to the demand for vaccines targeting conditions prevalent in older adults, such as shingles and pneumococcal diseases. Pharmaceutical companies and biotech firms are increasingly focusing on vaccine research and development. Partnerships between industry players and research institutions, along with advancements in vaccine manufacturing technologies, drive innovation and contribute to the growth of the vaccine market. Besides, the growing importance of travel vaccines, as people increasingly engage in international travel, adds to market expansion. Vaccines for diseases prevalent in different regions become essential for travelers, promoting a global market for travel-related immunizations.

United States Vaccines Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on technology, patient type, indication, route of administration, product type, treatment type, end user, and distribution channel.

Technology Insights:

https://www.imarcgroup.com/CKEditor/4df2be45-fb2f-4a09-890a-76b18e7708deother-regions1.webp" style="height:450px; width:800px" />

• Conjugate Vaccines
• Inactivated and Subunit Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• Toxoid Vaccines
• Others
  

The report has provided a detailed breakup and analysis of the market based on the technology. This includes conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, toxoid vaccines, and others.

Patient Type Insights:

• Pediatric
• Adult
  

A detailed breakup and analysis of the market based on patient type have also been provided in the report. This includes pediatric and adult.

Indication Insights:

• Bacterial Diseases
  • Meningococcal Disease
  • Pneumococcal Disease
  • Diphtheria/Tetanus/Pertussis (DPT)
  • Tuberculosis
  • Haemophilus Influenzae (Hib)
  • Typhoid
  • Others
• Viral Diseases
  • Hepatitis
  • Influenza
  • Human Papillomavirus (HPV)
  • Measles/Mumps/Rubella (MMR)
  • Rotavirus
  • Herpes Zoster
  • Varicella
  • Japanese Encephalitis
  • Rubella
  • Polio
  • Rabies
  • Dengue
  • Others
    

The report has provided a detailed breakup and analysis of the market based on the indication. This includes bacterial diseases (meningococcal disease, pneumococcal disease, diphtheria/tetanus/pertussis (DPT), tuberculosis, haemophilus influenzae (HIB), typhoid, and others) and viral diseases (hepatitis, influenza, human papillomavirus (HPV), measles/mumps/rubella (MMR), rotavirus, herpes zoster, varicella, Japanese encephalitis, rubella, polio, rabies, dengue, and others).

Route of Administration Insights:

• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others
  

A detailed breakup and analysis of the market based on route of administrations have also been provided in the report. This includes intramuscular and subcutaneous administration, oral administration, and others.

Product Type Insights:

• Multivalent Vaccine
• Monovalent Vaccine
  

<p

Global Infectious Vaccines market size 2025 was XX Million. Infectious Vaccines Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

Global Therapeutic Vaccines Market market size valued at US$ 25.82 Billion in 2023, set to reach US$ 123.12 Billion by 2032 at a CAGR of about 16.9% from 2024 to 2032.

Snapshot img

Vaccine Research Market Size 2024-2028

The vaccine research market size is forecast to increase by USD 21.4 billion at a CAGR of 10.84% between 2023 and 2028. The market is witnessing substantial growth due to the persistently high prevalence of infectious diseases and the requirement for innovative vaccines to address chronic infections. Additionally, the advancement of adjuvants and vaccine delivery systems is significantly contributing to market expansion. This growth is driven by the increasing demand for efficient, accessible, and high-standard solutions. Companies in this sector are adapting their strategies to align with these trends, focusing on sustainability and operational efficiency to remain competitive. The market's future direction is influenced by these key drivers, ensuring its continued growth and evolution. As the industry progresses, the demand for advanced solutions continues to expand its scope.

What will be the size of the Vaccine Research Market during the forecast period?

Request Free Vaccine Research Market Sample

Vaccine Research Market Segmentation

The Vaccine Research market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

End-user

  Public
  Private


Age Group

  Pediatric
  Adult


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

Which is the largest segment driving market growth?

The public segment is estimated to witness significant growth during the forecast period.

Government entities, including the US National Institute of Allergy and Infectious Diseases (NIAID) and the US National Institutes of Health (NIH), play a significant role in vaccine research. In response to the COVID-19 pandemic, governments worldwide have made substantial investments in vaccine development, from basic science and pre-clinical stages through clinical trials. These efforts led to the creation of several effective COVID-19 vaccines. Governments have been instrumental in funding and supporting each phase of the vaccine development process. Immunization programs focus on various diseases, such as pneumococcal disease, measles, mumps, mono, and varicella, diphtheria, tetanus, HPV, MMR, rotavirus, influenza, hepatitis, typhoid, meningococcal, rabies, Japanese encephalitis, yellow fever, and polio.

Vaccines come in various forms, including injectable, oral, and nasal, and are produced by vaccine manufacturers, genomic research centers, academic institutions, and private laboratories. They are used in hospital settings, clinics, and pharmacies. Vaccines protect against microorganisms, toxins, and surface proteins, enhancing the immune system's response to pathogens. Vaccine research continues to address physiological disorders, allergies, cancer, and infectious diseases, such as hypertension, dyslipidemia, Alzheimer's, inflammatory diseases, and self-antigens. Vaccines are available as combination vaccines, monovaccines, subunit, recombinant, polysaccharide, live-attenuated vaccines, inactivated vaccines, and DNA vaccines. Vaccines are crucial components of preventive healthcare and public health initiatives, reducing morbidity and mortality.

Get a glance at the market share of various regions. Download the PDF Sample

The Public segment was valued at USD 12.10 billion in 2018 and showed a gradual increase during the forecast period.

Which region is leading the market?

North America is estimated to contribute 44% to the growth of the global Vaccine Research market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.The market in North America is significantly driven by the high prevalence of both infectious and non-infectious diseases. In the US, influenza, hepatitis A, hepatitis B, HIV, measles, malaria, tuberculosis, and cancer are among the most common health concerns. The prevalence of these diseases continues to increase, particularly in developed countries. For instance, influenza cases peak annually in the US during November to February. Although vaccines have led to a decline in diseases like mumps, measles, and rubella (MMR), they have not been eradicated completely. Vaccine research focuses on various types, including conjugate, recombinant, live attenuated, toxoid, and inactivated vaccines.

These vaccines target various diseases, such as meningitis, pneumonia, and polio. Stakeholders In the market include government immunization programs, preventive healthcare providers, vaccine manufacturers, genomic research centers, academic institutions, private laboratori

The Therapeutic Vaccine Market is Segmented by Products (Autoimmune Disease Vaccines, Neurological Disease Vaccines, Cancer Vaccines, Infectious Disease Vaccines, and Other Products), Technology (Allogeneic Vaccine and Autologous Vaccine), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The report offers the value (in USD million) for the above segments.

Snapshot img

Human Combination Vaccines Market Size 2024-2028

The human combination vaccines market size is forecast to increase by USD 7.03 billion at a CAGR of 8.69% between 2023 and 2028.

The market is experiencing significant growth due to several key trends and challenges. One of the primary drivers is the increasing antiviral drug resistance, which has led to a greater emphasis on preventive measures through vaccines. Additionally, the threat from bioterrorism has heightened the need for effective combination vaccines to protect against multiple diseases simultaneously. Vaccine distribution challenges, such as vaccine refrigeration and packaging, are significant considerations in the market. Furthermore, the consolidation of different immunization schedules is streamlining vaccine administration and increasing convenience for healthcare providers and patients. These trends are shaping the market and are expected to continue driving growth In the coming years.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market encompasses the production and distribution of vaccines that protect against multiple diseases with a single administration. This market is driven by the newborn population growth and the ongoing need for pediatric immunization. Inactivated virus vaccines and live attenuated vaccines are the primary types of combination vaccines, each offering unique advantages in terms of vaccine safety, effectiveness, and ease of administration. Immunization coverage rates vary globally, with ongoing efforts to increase vaccination adoption and combat vaccine resistance. The threat of bioterrorism and emerging infectious diseases further underscores the importance of vaccine development and immunization campaigns.
The global vaccine market is experiencing steady growth, fueled by advancements in vaccine technology, including pathogen inactivation and multi-dose vaccine administration. Vaccine compliance remains a crucial factor, with ongoing initiatives to improve vaccine safety, effectiveness, and vaccine compliance. The vaccine supply chain is a critical component of the market, with ongoing efforts to ensure a reliable and efficient distribution network. Disease prevention remains the primary focus of the market, with ongoing research and development aimed at addressing vaccine resistance and emerging diseases. The market is expected to continue growing, driven by the need to protect global populations from infectious diseases and ensure public health and safety.

How is this Industry segmented and which is the largest segment?

The industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  Inactivated vaccine
  Live attenuated vaccine


Channel

  Hospitals
  Retailers
  Online


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    Japan


  Rest of World (ROW)

By Type Insights

The inactivated vaccine segment is estimated to witness significant growth during the forecast period.The inactivated segment dominates The market due to its superior tolerability and fewer complications when multiple antigens are used. Inactivated human combination vaccines, such as those for Chickenpox, DTaP, IPV, Pediarix, Pentacel, and Tetraxim, are preferred due to their ability to provide comprehensive protection against various diseases. However, producing these vaccines poses challenges due to potential antigen incompatibilities and interactions among ingredients. Inactivated vaccines are developed using pathogen particles that have been destroyed or killed, ensuring a strong immune response against the targeted organisms. Medical practitioners prioritize these vaccines due to their effectiveness in preventing diseases, including Diphtheria, Tetanus, Acellular pertussis, Polio, and Hib.

Get a glance at the market report of share of various segments Request Free Sample

The inactivated vaccine segment was valued at USD 8.8 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

The North American market holds the largest share in 2023, driven by stringent regulatory policies mandating infant vaccination. Despite a slower growth rate due to decreasing infectious disease prevalence, the market expansion is fueled by ongoing initiatives to promote vaccine usage. In other regions, the market is driven by the rising incidence of di

Global Anti-Infective Vaccines Market was valued at $4.93 Billion in 2023 and is projected to $10.35 Billion by 2032, at a CAGR of 8.6% from 2024 to 2032.

The size and share of the market is categorized based on Application (Infectious Disease, Cancer, Other) and Product (Individualized Cancer Treatment MRNA Vaccine, Infectious Disease Treatment MRNA Vaccine, Infection Prevention MRNA Vaccine) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

The size and share of the market is categorized based on Type (Live, Inactivated) and Application (Veterinary Pharmacy, Online Sale, Others) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

Anti-Infective Vaccines Market size is expected to develop revenue and exponential market growth at a remarkable CAGR during the forecast period from 2024-2032

Snapshot img

Vaccines Market Size 2025-2029

The vaccines market size is forecast to increase by USD 193.7 billion at a CAGR of 23% between 2024 and 2029.

The market is experiencing robust growth, driven by several key factors. Increased funding for vaccine development and the launch of new vaccines are major catalysts, particularly for chronic infections where novel solutions are in high demand. Another significant trend is the increasing use of adjuvants in vaccines, which enhance their efficacy and broaden their application. These developments reflect the market's response to the growing demand for advanced, innovative solutions. Moreover, advancements in medical technology and changing consumer preferences are shaping the market landscape. There is a transition towards more efficient systems, better accessibility, and higher industry standards. 
The vaccine market's future growth is underpinned by these drivers, which continue to influence its direction. As the market evolves, efforts to meet the growing demand for advanced solutions are expanding its scope, ensuring long-term growth. The industry's focus on delivering innovative, effective vaccines is a testament to its commitment to addressing global health challenges posed by infectious diseases and improving overall public health.

What will be the size of the market during the forecast period?

Request Free Sample

Vaccines Market Segmentation

The vaccines market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.TypeHuman vaccineAnimal vaccineEnd-userHospitalsClinicsRoute of AdministrationOralParenteralNasalOralParenteralNasalAge GroupPediatricAdultPediatricAdultTechnologyConjugateRecombinantLive AttenuatedOthersDiseaseViralBacterialParasiticOthersGeographyNorth AmericaUSCanadaEuropeFranceGermanyRussiaUKAsiaRest of World (ROW)

Which is the largest segment driving market growth?

The human vaccine segment is estimated to witness significant growth during the forecast period. The human market encompasses a vast array of products designed to prevent infectious diseases and foster global health. These vaccines function by stimulating the immune system to respond to specific pathogens, thereby conferring immunity against various diseases. Human vaccines can be classified into several types based on their composition, mechanism of action, and target population. One significant category is inactivated or killed vaccines, which utilize heat, chemicals, or radiation to render pathogens non-infectious. Examples include the inactivated polio vaccine (IPV) and influenza vaccine. These vaccines offer increased safety for individuals with compromised immune systems but may necessitate multiple doses to achieve adequate immunity.

Other types of human vaccines include therapeutic vaccines, conjugate vaccines, recombinant vaccines, live attenuated vaccines, toxoid vaccines, and subunit vaccines. These vaccines play a pivotal role in protecting billions of people from diseases and promoting overall health.

Get a glance at the market share of various regions. Download the PDF Sample

The Human vaccine segment was valued at USD 57.40 billion in 2019 and showed a gradual increase during the forecast period.

Advancements in vaccine development are being driven by cutting-edge technologies such as nanoparticle vaccines and mRNA platforms, which enable highly targeted immune responses. The incorporation of adjuvant systems and immune modulators enhances vaccine efficacy, while viral vectors, DNA vaccines, and synthetic peptides offer diverse strategies for antigen design. Needle-free delivery methods, such as microneedle patches, are improving patient comfort and access, with the potential to revolutionize immunization tech. Innovations in cold chain technology and smart packaging, paired with digital tracking and blockchain records, ensure the safe transport and storage of vaccines. AI diagnostics and machine learning-driven predictive models are accelerating the development and evaluation of vaccines, while bioengineering tools enable precision dosing and rapid production. In addition, recombinant proteins, conjugate systems, and live attenuated or toxoid formulas continue to offer robust options for therapeutic vaccines. The use of sustainable materials and eco-friendly vials further reflects the growing focus on environmentally conscious practices in vaccine production. Data analytics are playing a pivotal role in optimizing vaccine delivery and monitoring outcomes.

Which region is leading the market?

North America is estimated to contribute 39% to the growth of the global market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

Technavio's analysts have elaborately explained the regio

GlaxoSmithKline was the global leader based on revenues generated through vaccine products in 2017 and is forecasted to maintain this position up to 2024. The London-based pharmaceutical manufacturer generates around one fifth of its total revenue through the vaccines segment. GlaxoSmithKline’s vaccines, among others, target meningitis, influenza, shingles, and hepatitis. Other top players in the global vaccine business are Merck & Co., Sanofi, and Pfizer.

Vaccine market overview
The vaccine market worldwide is expected to increase with a compound annual growth rate of seven percent between 2017 and 2024. A main driver of the growth is the increase of various infectious diseases like influenza, swine flu, hepatitis, tuberculosis, diphtheria, Ebola, and meningococcal and pneumococcal diseases. The United States are the world’s largest national market for vaccines, while North America is, accordingly, the largest regional market, followed by Europe. Vaccines which are administered intramuscularly make up over half of global revenues, while vaccines which are administered subcutaneously make up around one fifth of the market. Pfizer’s Prevnar 13 is currently the world’s top vaccine product, generating around 5.7 billion U.S. dollars of revenue.

The impact of vaccines   Originally, the main aim of vaccinations (immunizations) was to prevent infections from certain diseases and thus to reduce outbreaks and larger epidemics within the population. Thanks to vaccines, infectious diseases which once had high death rates like polio and smallpox have been nearly eradicated. Others, like measles, mumps, and whooping cough, are mostly under control. However, vaccines can also be used after an infection occurs as a therapeutic. Therapeutic vaccines in immuno-oncology are one of the latest big things in cancer treatment.

The size and share of the market is categorized based on Type (Inactivated vaccines, Conjugate vaccines, Live/attenuated vaccines) and Application (Bacterial diseases, Viral diseases) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

The Report Covers mRNA Therapeutics Manufacturing Companies and it is Segmented by Vaccine Type (Self-amplifying mRNA-based Vaccines and Conventional Non-amplifying mRNA-based Vaccines), Application (Cancer, Infectious Diseases, Autoimmune Diseases, and Other Applications), Treatment Type (Monoclonal Antibody, Gene Therapy, Cell Therapy, and Other Treatment Types), End User (Research Laboratories and Organizations, Hospitals, and Clinics and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

The Global Vaccine market is anticipated to cross USD 105 Billion by 2028 due to growing global health concern and infectious disease rise the demand.

Snapshot img

Travel Vaccines Market Size 2024-2028

The travel vaccines market size is forecast to increase by USD 3.97 billion at a CAGR of 8.64% between 2023 and 2028. The market is experiencing significant growth due to several key factors. The rise in international vacations and medical tourism has led to an increase in the number of travelers, thereby driving demand for travel vaccines. Additionally, changes in the demographic profiles of travelers, such as an aging population and an increase in immunocompromised individuals, have heightened the need for protection against microbes and pathogenic organisms. Furthermore, the lack of comprehensive coverage for travel vaccines in health plans has created a gap in the market that vaccine manufacturers are looking to fill. Attaining immunity through vaccines is crucial for travelers to protect themselves from diseases while exploring new destinations.

Request Free Sample

The market plays a crucial role in ensuring the health and safety of travelers as they explore various parts of the world. With the increasing trend of overseas travel, the likelihood of encountering vaccine-preventable diseases has become a significant concern. Travel-related diseases pose health hazards for travelers, and the use of vaccines is an essential measure to prevent the spread of these diseases. Vaccines are essential tools in the fight against infectious diseases, including those that are prevalent in different regions. Diseases such as measles, mumps, rubella, hepatitis A and B, typhoid, yellow fever, and rabies are common among travelers.

Furthermore, the use of specialized vaccines, such as recombinant DNA technology and mRNA vaccines, have revolutionized the market, providing effective and safe solutions against various pathogens. Biotechnology has significantly contributed to the development of travel vaccines, enabling the production of attenuated organisms and pathogenic organisms that stimulate the immune system to build immunity against diseases. The prevalence of disease strains varies from region to region, and initiatives to develop vaccines against these strains are ongoing to ensure travelers are protected. Infectious diseases spread through microbes, and the market offers vaccines against various diseases caused by these microbes. For instance, yellow fever is caused by a virus, while typhoid fever is caused by Salmonella typhi bacteria.

Moreover, vaccines are the most effective means of preventing these diseases and ensuring travelers' health and safety. The use of travel vaccines is essential for travelers, especially those visiting regions with high disease prevalence. Diseases such as cholera, hepatitis A and E, and malaria are common in certain regions, and vaccines are the most effective means of preventing these diseases. Travelers are advised to consult their healthcare providers before traveling to determine which vaccines they need based on their travel destination. The gains of the market are significant, as they not only protect travelers but also contribute to global health initiatives.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Disease Type

  Influenza
  Diptheria
  Hepatitis
  Typhoid and others


End-user

  Adult vaccines
  Pediatric vaccines


Geography

  North America

    US


  Europe

    Germany
    UK


  Asia

    China
    Japan


  Rest of World (ROW)

By Disease Type Insights

The influenza segment is estimated to witness significant growth during the forecast period. The market for travel vaccines, specifically those for influenza, is poised for substantial expansion during the forecast period. The prevalence of influenza continues to increase and is projected to continue doing so. For instance, the Centers for Disease Control and Prevention (CDC) reports that influenza virus infections led to between 8.1 and 13.9 million illnesses, 3.7 and 6.1 million doctor visits, 81,000 and 171,000 hospitalizations, and 5,000 and 14,000 deaths in the US between early October 2021 and mid-June 2022.

Get a glance at the market share of various segments Request Free Sample

The influenza segment was valued at USD 3.34 billion in 2018 and showed a gradual increase during the forecast period.

Regional Insights

North America is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions Request Free Sample

The market in North America is expected to maintain its leading position in the global market due to the significant presence of travel

Cattle Vaccines Market Size And Forecast

Cattle Vaccines Market size was valued at USD 13.07 Billion in 2023 and is projected to reach USD 21.33 Billion by 2031, growing at a CAGR of 6.32% during the forecast period 2024-2031.

Global Cattle Vaccines Market Drivers

The market drivers for the Cattle Vaccines Market can be influenced by various factors. These may include:

Growing Rate Of Diseases In Cattle: Effective vaccines are in high demand in order to protect cattle from infectious diseases such as brucellosis, foot-and-mouth disease, and viral diarrhoea in cows.

Growing Requirement For Animal-Based Protein: The growing number of people on the planet has increased demand for dairy and meat products, which calls for robust herds of cattle. In order to prevent disease outbreaks and maintain constant production, this demand drives the need for vaccines.

Technological Developments In Vaccines: The creation of more potent and effective vaccinations, particularly those that provide extended immunity and broad-spectrum protection, has been facilitated by advancements in immunology and biotechnology. These developments support market expansion.

Governmental Proposals And Assistance: Worldwide, a large number of governments carry out immunisation campaigns and offer financial assistance or subsidies for veterinary services, which includes vaccinations for cattle. These programmes aid in the prevention of livestock illnesses and promote market expansion.

Raising Preventive Healthcare Awareness And Adoption: Vaccination rates are rising as a result of farmers and livestock owners’ growing awareness of the advantages of preventive care for cattle. This is largely due to the education and outreach initiatives that veterinary businesses and organisations run.

Growth Of The Meat And Dairy Industries: The need for cow vaccinations is driven by the expansion of the meat and dairy industries, particularly in emerging economies. The necessity of keeping sizable, healthy herds grows as these sectors develop.

Livestock Diseases’ Effects On The Economy: Cattle disease outbreaks can have serious economic repercussions, such as reduced production, trade restrictions, and animal losses. Vaccination is a reasonably priced way to reduce these dangers, which is fueling demand.

Creation Of Novel And Better Vaccines: New vaccinations with improved protection, fewer side effects, and simpler administration are introduced as a result of ongoing research and development efforts, which has a favourable effect on market expansion.

Standards And Regulations: Vaccine usage is encouraged by strict laws and guidelines pertaining to the health and safety of animals. Adherence to these standards is crucial for the commerce and export of livestock, hence promoting the implementation of vaccination campaigns.

Growing The Population Of Livestock: The number of animals worldwide is increasing, especially in emerging nations where raising cattle is a major source of income. More vaccinations are required to prevent and manage diseases in a greater population of cattle.

The global vaccine market is showing some escalating growth and it is expected that it will reach total revenues of nearly 60 billion U.S. dollars by 2020. That would be almost double the size the market had back in 2014. Driver of the growth is the increase of various infectious diseases like influenza, swine flu, hepatitis, tuberculosis, diphtheria, Ebola, and meningococcal and pneumococcal diseases. Leading manufacturers of vaccines are big pharma companies like GlaxoSmithKline, Merck & Co., and Pfizer.

How vaccines work

The concept behind the functioning of vaccines - also known as immunizations - is relatively simple: inject a weakened form, or a fragment, of a disease to a person so the body learns to produce antibodies or to start other processes of immunity. As a result, the person’s body is ready to fight the same infection next time. By this way, infectious diseases which once had high death rates like polio and smallpox have been nearly eradicated. Others like measles, mumps, and whooping cough, are mostly under control and larger epidemics have been successfully prevented. While some immunizations last lifelong, others have to be renewed to stay efficient. Despite the obvious success of immunizations and their huge role for public health, there are discussions about the safety and consequences of vaccines in the U.S. and many other countries.

The vaccine market

At this moment, Pfizer’s Prevnar 13 is the world’s leading vaccine product, generating around 5.7 billion U.S. dollars of revenue. Prevnar 13 is a vaccine for the prevention of invasive disease caused by 13 streptococcus pneumoniae strains and can be used in children and adults. The United States are the world’s largest national market for vaccines, while North America is, accordingly, the largest regional market. The global vaccine market is largely dominated by vaccines which are administered intramuscularly. These vaccines make up over half of global revenues, while vaccines which are administered subcutaneously make up around one fifth of the market. Other common routes of administration are oral or intravenous.

The global Pediatric Vaccines Market is expected to reach a value of USD 45.48 billion by 2033, growing at a CAGR of 4.1% from 2025 to 2033. The increasing incidence of infectious diseases, technological advancements in vaccine development, and the growing demand for safe and effective vaccines for children are driving the market growth. The market is segmented based on type (monovalent, multivalent), technology (live attenuated, inactivated, subunit), application (infectious diseases, cancer), and region. The key players in the Pediatric Vaccines Market are AstraZeneca, Sanofi, GSK plc, Pfizer, Inc., Zydus Group, Indian Immunologicals Ltd., Serum Institute of India Pvt. Ltd., Panacea Biotec, SINOVAC, and BIO-MED. These companies are investing heavily in research and development to develop new and innovative vaccines. The market is also seeing an increase in mergers and acquisitions, as larger companies seek to expand their portfolio of vaccines. The market is expected to see continued growth in the future, as the demand for pediatric vaccines continues to increase. Recent developments include: In March, 2024 European commission approved Pfizer's PREVENAR 20, a vaccine offering the broadest serotype coverage to protect children against pneumococcal disease. This approval is based on extensive Phase 3 trial data demonstrating its safety and effectiveness. It follows similar approvals in the U.S., Canada, Australia, and other countries. , In November, 2023 Indian Immunologicals Limited (IIL) has launched a new measles and rubella vaccine for children, named Mabella. Developed in partnership with the Polyvac Institute of Vietnam, the live-attenuated vaccine has undergone rigorous clinical trials, demonstrating both safety and efficacy. This launch coincides with the 25th anniversary of IIL’s Human Biologicals Institute, highlighting the company’s ongoing contributions to vaccine development and disease control in India. , In May, 2023 Phase IIIb HARMONIE trial data was presented at the European Society for Paediatric Infectious Diseases meeting which demonstrated that Beyfortus (nirsevimab) significantly reduced hospitalizations due to RSV lower respiratory tract infections in infants under 12 months by 83.2%. Additionally, it showed a 75.7% reduction in very severe RSV LRTI hospitalizations, with Beyfortus maintaining a favorable safety profile. These results reinforce Beyfortus' potential to significantly relieve the burden of RSV on healthcare systems and families. .

The size of the Human Vaccine Market was valued at USD 50.74 billion in 2024 and is projected to reach USD 95.71 billion by 2033, with an expected CAGR of 9.49% during the forecast period. This expansion is fueled by several key factors. The increasing prevalence of infectious diseases, coupled with rising public awareness of the importance of vaccination, forms a strong foundation for market growth. Government initiatives promoting vaccination programs, particularly in developing nations, significantly contribute to market expansion. Furthermore, advancements in vaccine technology, such as mRNA vaccines and novel delivery systems, are driving innovation and broadening the market's potential. The development of multivalent vaccines, offering protection against multiple diseases simultaneously, is also contributing to the market's expansion. Finally, increased research and development efforts by pharmaceutical companies, coupled with strategic collaborations and mergers and acquisitions, are accelerating the introduction of new and improved vaccines, further fueling market growth.